Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors

详细信息    查看全文

• 作者：Fabrizio Carnevale-Schianca¹ ; ^{fabrizio.carnevale@ircc.it} ; Daniela Caravelli¹ ; Susanna Gallo¹ ; ² ; Valentina Coha¹ ; Lorenzo D'Ambrosio² ; ³ ; Elena Vassallo⁴ ; Marco Fizzotti³ ; Francesca Nesi⁴ ; Luisa Gioeni⁵ ; Massimo Berger⁴ ; Alessandra Polo⁶ ; Loretta Gammaitoni³ ; Paolo Becco¹ ; ² ; Lidia Giraudo³ ; Monica Mangioni⁶ ; Dario Sangiolo² ; ³ ; Giovanni Grignani³ ; Delia Rota&ndash ; Scalabrini³ ; Antonino Sottile⁶ ; Franca Fagioli⁴ ; ^&dagger ; ; Massimo Aglietta¹ ; ² ; ³ ; ^&dagger ;
• 关键词：Allogeneic bone marrow transplantation ; Graft-versus-host disease ; Post-transplant cyclophosphamide
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：23
• 期：3
• 页码：459-466
• 全文大小：590 K
• 卷排序：23

文摘

Post-transplant cyclophosphamide was safely conjugated with 1 of the most-used GVHD prophylaxis regimens. Nonrelapse mortality was contained to 3% at 2 years. Extremely low acute and chronic GVHD rates (17% and 7%) allowed limited steroid and immunosuppressive drug use. Most nonrelapsing patients can live without chronic GVHD therapy. The presented strategy appears to be widely reproducible across most transplant centers.